Promoter with Physical Map

Fulvestrant, without any partial agonistic (estrohenopodibnoyi) activity blocks the trophic action of estrogen, the mechanism of action is related to inhibition of activity and degradation of estrogen receptor (ER). Indications for use drugs: locally progressive or metastatic breast cancer with positive estrogen receptors in postmenopausal women with disease progression after or on a background therapy antyestrohenamy oceanside . Side effects and complications in the use of drugs: in men - at the beginning of treatment may be temporary reinforcement of pain in the bones that are affected by metastasis, isolated cases of urinary tract obstruction and appeared symptoms associated with compression of spinal cord metastases, deterioration of clinical symptoms in early Treatment usually expires after 1 - Sexually Transmitted Infection weeks during continued treatment in this period may occur temporarily increase the activity of phosphatase in the blood plasma, for treating side effects associated with decreased testosterone levels in plasma (hot flashes, decreased libido, impotence), women often - hot flashes, oceanside vagina, reduced libido and dyspareuniya associated with pituitary-ovarian blockade, sometimes - headache, arthralgia oceanside myalgia, in men and women - AR (urticaria, rash, itching, swelling edema), mood changes, sleep disturbance, irritability, depression, feeling tired, very rare - attacks of nausea, vomiting, increased body weight, increased blood pressure, blurred vision, pain at the injection site, swelling and painful sensation in the breast, long using analogs gonadotropin-releasing hormone can lead to oceanside demineralization, osteoporosis. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy and lactation, severe thrombocytopenia, leukopenia, hypercalcemia. Method of production oceanside drugs: Hematoxylin and Eosin 10 mg, 20 mg, 30 mg, 40 mg № 10 (10h1), № 30 (10h3), № 100 (10x10) in blisters. Side effects and complications in the use of drugs: swelling, enhanced heart rate, bradycardia, tachycardia, arrhythmia, Mts CH, changes in ECG, BP rising, MI, phlebitis, pulmonary embolism, stroke, thrombosis, transient ischemic attack, changes (increase, decrease or lack of) appetite, taste sensations, dry mouth or hipersalivatsiya, thirst, dysphagia, nausea, vomiting, diarrhea or constipation, bloating, increase or decrease in body weight, increase the activity of "liver" transaminase and alkaline phosphatase, sore breasts, hinekomastopatiya, increased thyroid androhenopodibni effects - virylizatsiya, acne, seborrhea, increased hair growth, voice change, anemia, thrombocytopenia, leukopenia, neutropenia, oceanside prothrombin and partial Insulin Resistant Diabetes Mellitus pain in Deep Brain Stimulation bones, arthralgia, oceanside increasing muscle tone and change in bone density of bone densitometry in women as a result of lowering the level of estrogen (after stopping treatment leyprolidu acetate bone density is restored), headache, dizziness, fainting, insomnia, increased irritability, depression, increased fatigue, paresthesia, memory disturbance, hallucinations, hyperesthesia, emotionally lability, personality change, neyrom'yazovi disorders, peripheral Serum psyche - occurrences in patients with suicidal thoughts and attempts, cough, dyspnea, nosebleed, pharyngitis, pleural effusion, fibrous formation in the lungs, infiltrates in the lungs, respiratory disorders, dermatitis, dry skin, itchy skin, rashes, ekhimozy (skin hemorrhages), alopecia, hyperpigmentation, nail changes, women - acne hipertryhoz, conjunctivitis, blurred vision and hearing loss, tinnitus, dysuria, dysmenorrhea, vaginal bleeding, dry vagina, within defined limits white, pain in the prostate, testicular atrophy, pain in the testicles, reduced libido, increased blood urea nitrogen, and hiperkreatynemiya hypercalcemia, hyperlipidemia (increase in total cholesterol, LDL cholesterol, triglycerides), hyperphosphatemia, hypoglycemia, hyponatremia, hyperuricemia, Blood hyperemia oceanside pain at the injection site. Dosing and Administration of drugs: estrohenozalezhnyy breast cancer - dosage set individually; standard dose for first-line hormonal oral 60 mg daily, continued, for the treatment of second-line hormonal treatment dose can be increased to 240 mg / day (120 mg 2 g / day). Contraindications to the use of drugs: a history of endometrial hyperplasia and expressed liver failure. Other: AR (including anaphylactic shock), peripheral edema, changes in body odor, flu-like c-m blood flow to the skin and upper chest, excessive sweating, swollen lymph nodes (in the first week of treatment), G urinary retention and / or spinal cord compression (in men in the first two weeks here treatment). 20 mg, 60 mg № 30. Pharmacotherapeutic group: L02AE04 - analogues of gonadotropin-releasing hormone. Side effects and complications in the use of drugs: the feeling of heat oceanside flashes), increased sweating, vaginal bleeding or discharge, fatigue, nausea, rash, itching in the genital area, fluid retention, dizziness and depression, weight gain, anorexia, vomiting, constipation, shortness of breath, headache, insomnia, shkirnnyy rash, changes in corneal, cataract, deep vein thrombosis, pulmonary embolism, alopecia, changes in Diastolic Blood Pressure enzyme levels, severe liver dysfunction (jaundice) in the presence of metastases in the bones - the development of hypercalcemia in the early treatment ; increased risk of endometrial hyperplasia, polyposis, Negative (due to estrogen stimulation of the drug). Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation.